Novo Holdings, the controlling shareholder of Danish pharmaceutical giant Novo Nordisk, experienced a substantial 35% decline in managed assets last year. The investment firm's leadership addressed the downturn while outlining future investment strategies. Despite the significant asset reduction, company executives indicated they would maintain their biotech investment approach.
The asset decline represents a major financial shift for one of the pharmaceutical industry's most influential investment entities. Novo Holdings serves as the investment arm behind Novo Nordisk, which has gained prominence through its diabetes and obesity treatments. The firm's investment decisions significantly impact biotech funding across global markets.